Journal of Clinical Medicine, 8 July 2019
—
Cannabidiol (CBD) is ubiquitous in state-based medical cannabis programs and consumer products for complementary health or recreational use. CBD has intrinsic pharmacologic effects and associated adverse drug events (ADEs) along with the potential for pharmacokinetic and pharm…
Current Neuropharmacology, 3 June 2019
—
BACKGROUND: Currently, there is great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD occurred in the 1970s and intensified recently with many discoveries about the endocannabinoid system. M…
This study, published in the June 2014 issue of the Journal of Clinical Psychopharmacology, describes more than 100 patients reporting about the therapeutic satisfaction with their pharmaceutical-grade cannabis product. Furthermore, differences in subjective effects among the available strains are investigated. Read More
Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review published in 2008 in the Journal of British Pharmacology focuses on the manner with which three of these compounds, (_)-trans-D9-tetrahydrocannabinol (D9-THC), (_)-cannabidiol (CBD) and (_)-trans-D9-tetrahydrocannabivarin (D9-THCV), interact with cannabinoid receptors CB1 and CB2. Read More
The role of the endocannabinoid system in nicotine addiction is being increasingly acknowledged. From the University College in London, this study published in the September 2013 issue of Addictive Behavior found that cannabidiol (CBD) reduces cigarette consumption in tobacco smokers. Read More
From the American Journal of Physiology – Heart and Circulatory Physiology published in September 2007, research from Israel has shown that CBD causes reduced infarct size in an in vivo rat model of ischemia and reperfusion. Furthermore, it seems that this effect is not direct and may be mediated by a reduced inflammatory response. Thus CBD may be a promising novel treatment for myocardial ischemia. Read More
Can CBD counteract adverse effects of excessive THC? In this 2010 issue of the journal Neuropsychopharmacology, they showed that pretreatment with CBD prevented the acute induction of psychotic symptoms by D-9-tetrahydrocannabinol. D-9-THC and CBD can have opposite effects on regional brain function, which may underlie their different symptomatic and behavioral effects, and CBD’s ability to block the psychotogenic effects of D-9-THC. Read More
A German review of the literature presenting current knowledge of the therapeutic benefits of medical cannabis.
University of Saskatchewan researchers have discovered a cannabis ‘pharma factory’, never before seen in plants. “What cannabis has done is take a rare fatty acid with a simple, six-carbon chain and use it as a building block to make something chemically complex and pharmacologically active.” Read More
Published in the British Journal of Psychiatry (2010) 197, 259-260.